Fu­ji­film is all in on AD­Cs, to sell ‘trust’ to boost man­u­fac­tur­ing rev­enues

Fu­ji­film Diosynth Biotech­nolo­gies will re­ceive “ag­gres­sive” in­vest­ment over the next three years from its par­ent com­pa­ny to lift rev­enues, as the CD­MO arm em­pha­sizes its track record and “trust” as sell­ing points to clients.

Fu­ji­film Hold­ings spelled out its vi­sion for growth up to 2030 on Wednes­day and, if ex­e­cut­ed as planned, Fu­ji­film Diosynth could rake in as much as 700 bil­lion yen ($4.5 bil­lion) in rev­enue by 2030, which is a 40% in­crease from 2023. Fu­ji­film will cap­i­tal­ize on the high de­mand for com­mer­cial man­u­fac­tur­ing of an­ti­body-drug con­ju­gates, ac­cord­ing to the pre­sen­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER